Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Oral GLP-1 drug linked to weight loss, cardiovascular benefits | Cardiologist agrees to pay $1.2M | Air purifiers vs. pollution

News You Need to Know Today
Oral GLP-1 drug linked to weight loss, cardiovascular benefits | Cardiologist agrees to pay $1.2M | Air purifiers vs. pollution
Monday, August 11, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Another win for Lilly: Oral GLP-1 drug linked to significant weight loss, other cardiovascular benefits

Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.

READ MORE >
weight loss scale overweight obese lose weight pounds
Share on Twitter Share on Facebook Share on Linkedin

Another win for Lilly: Oral GLP-1 drug linked to significant weight loss, other cardiovascular benefits

Share on Twitter Share on Facebook Share on Linkedin
weight loss scale overweight obese lose weight pounds
Tirzepatide and semaglutide are getting the attention now, but orforglipron could be the next go-to drug for patients hoping to lose weight and improve their heart health—no injections required.
READ MORE >

Texas cardiologist to pay $1.2M for allegedly prescribing opioids to himself

The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 

READ MORE >
pain pills opioids
Share on Twitter Share on Facebook Share on Linkedin

Texas cardiologist to pay $1.2M for allegedly prescribing opioids to himself

Share on Twitter Share on Facebook Share on Linkedin
pain pills opioids
The interventional cardiologist was accused of prescribing a variety of drugs to his family and friends, but then picking them up himself for his own personal use. This settlement officially resolves those allegations. 
READ MORE >

Air purifiers may reduce cardiovascular risks from pollution and wildfires

Multiple studies in recent years have linked poor air quality to significant cardiac risks. Air filters, however, have shown potential to help combat these risks.

READ MORE >
Wildfire pollution image. Photo courtesy of the American Heart Association.
Share on Twitter Share on Facebook Share on Linkedin

Air purifiers may reduce cardiovascular risks from pollution and wildfires

Share on Twitter Share on Facebook Share on Linkedin
Wildfire pollution image. Photo courtesy of the American Heart Association.
Multiple studies in recent years have linked poor air quality to significant cardiac risks. Air filters, however, have shown potential to help combat these risks.
READ MORE >

Featured Articles

Cardiovascular IT systems keep evolving with AI, Epic integration on the rise

A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. 

READ MORE >
Healthcare IT analyst Amy Thompson from Signify Research explains trends in cardiology information systems at ACC 2025.
Share on Twitter Share on Facebook Share on Linkedin

Cardiovascular IT systems keep evolving with AI, Epic integration on the rise

Share on Twitter Share on Facebook Share on Linkedin
Healthcare IT analyst Amy Thompson from Signify Research explains trends in cardiology information systems at ACC 2025.
A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. 
READ MORE >

Too much screen time is bad for the heart

The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Too much screen time is bad for the heart

Share on Twitter Share on Facebook Share on Linkedin
The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood. 
READ MORE >

New liquid embolic agent for hypervascular tumors gains FDA’s premarket approval

Instylla's Embrace Hydrogel Embolic System minimizes bleeding risks during the embolization of hypervascular tumors in the peripheral arteries.

READ MORE >
Instylla Embrace Hydrogel Embolic System
Share on Twitter Share on Facebook Share on Linkedin

New liquid embolic agent for hypervascular tumors gains FDA’s premarket approval

Share on Twitter Share on Facebook Share on Linkedin
Instylla Embrace Hydrogel Embolic System
Instylla's Embrace Hydrogel Embolic System minimizes bleeding risks during the embolization of hypervascular tumors in the peripheral arteries.
READ MORE >

In Case You Missed It

New gene therapy for rare heart condition gains FDA’s fast track designation

Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. 

READ MORE >
Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.
Share on Twitter Share on Facebook Share on Linkedin

New gene therapy for rare heart condition gains FDA’s fast track designation

Share on Twitter Share on Facebook Share on Linkedin
Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.
Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. 
READ MORE >

Interest rising in CKM syndrome as connections become clearer

Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend.

READ MORE >
Joshua Joseph, MD, MPH, FAHA an expert in Cardiovascular-Kidney-Metabolic (CKM) syndrome, associate professor of internal medicine, and the Endowed Professor for Research in Internal Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, explains the CKM advisory from the American Heart Association designed to help define and stage the disease. CKM has seen a large amount of growing interest from cardiologists in recent years.
Share on Twitter Share on Facebook Share on Linkedin

Interest rising in CKM syndrome as connections become clearer

Share on Twitter Share on Facebook Share on Linkedin
Joshua Joseph, MD, MPH, FAHA an expert in Cardiovascular-Kidney-Metabolic (CKM) syndrome, associate professor of internal medicine, and the Endowed Professor for Research in Internal Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, explains the CKM advisory from the American Heart Association designed to help define and stage the disease. CKM has seen a large amount of growing interest from cardiologists in recent years.
Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend.
READ MORE >

Trump administration takes aim at ultra-processed foods, highlighting heart risks

The FDA and other federal agencies believe limiting ultra-processed foods can help "Make America Healthy Again." They highlighted years of research linking these foods to increased risks of cardiovascular disease, type 2 diabetes and other conditions. 

READ MORE >
Trump and Robert F. Kennedy Jr., secretary of health and human services (HHS). White House press photo
Share on Twitter Share on Facebook Share on Linkedin

Trump administration takes aim at ultra-processed foods, highlighting heart risks

Share on Twitter Share on Facebook Share on Linkedin
Trump and Robert F. Kennedy Jr., secretary of health and human services (HHS). White House press photo
The FDA and other federal agencies believe limiting ultra-processed foods can help "Make America Healthy Again." They highlighted years of research linking these foods to increased risks of cardiovascular disease, type 2 diabetes and other conditions. 
READ MORE >

In Other News

4 ways clinical AI can complement—rather than compete with—patient-centered care

If humanistic medicine is to endure the slow-motion AI tsunami flooding the healthcare landscape, humans will have to see those two forces—humanistic medicine and healthcare AI—not as oppositional to each other but as potentially synergistic. 

READ MORE >
newborn sibling nurse
Share on Twitter Share on Facebook Share on Linkedin

4 ways clinical AI can complement—rather than compete with—patient-centered care

Share on Twitter Share on Facebook Share on Linkedin
newborn sibling nurse
If humanistic medicine is to endure the slow-motion AI tsunami flooding the healthcare landscape, humans will have to see those two forces—humanistic medicine and healthcare AI—not as oppositional to each other but as potentially synergistic. 
READ MORE >

Healthcare AI today: AMA drills into Trump plan, Illinois forbids AI talk therapy, Mayo Clinic speeds ahead (again)

The AMA doesn’t refute much of the Trump AI Action Plan so much as amplify some of its talking points. One exception is the plan’s open disdain for ‘woke’ AI.

READ MORE >
Domo Origato Mr Roboto
Share on Twitter Share on Facebook Share on Linkedin

Healthcare AI today: AMA drills into Trump plan, Illinois forbids AI talk therapy, Mayo Clinic speeds ahead (again)

Share on Twitter Share on Facebook Share on Linkedin
Domo Origato Mr Roboto
The AMA doesn’t refute much of the Trump AI Action Plan so much as amplify some of its talking points. One exception is the plan’s open disdain for ‘woke’ AI.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Hypertension, RAAS inhibitors & COVID-19 | How a single question improves CAC scanning | New ACC virtual meetings
'World's smallest heart pump' gains key FDA approval | Indoor air filters & blood pressure | Keeping COVID-19 at bay
Week in Review: 4 cardiac arrhythmias associated with COVID-19 |Catheter ablation & AFib | CV health and race
FFR-guided PCI | Improving TAVR outcomes | Welldoc receives additional FDA approval
Catheter ablation for AFib | Conscious sedation & TAVR outcomes | Global guidelines for hypertension
Ticagrelor use approved for high-risk CAD patients | Tracking prescription trends during the pandemic
Abiomed's new FDA approval | Cardiovascular groups denounce racism, violence | NOACs outperform warfarin

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …338
    • Page 339
    • Page 340
    • Page 341
    • Current page 342
    • Page 343
    • Page 344
    • Page 345
    • Page 346 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup